Summit Therapeutics (SMMT) Set to Post Earnings on Monday

Key Points

• Summit Therapeutics is expected to report Q3 2026 results after market close on November 9; analysts forecast a loss of about $0.28 per share and revenue of $0.11 million.
• Shares recently traded at $15.74, below their 50- and 200-day averages of roughly $16.15–$16.16, and well below the one-year high of $29.23.
• Analyst sentiment is a Moderate Buy, with an average price target of $28.61; ratings include 11 Buy or Strong Buy, seven Hold, and one Sell.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.2817) per share and revenue of $0.11 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 7:00 AM ET.

Summit Therapeutics Price Performance

Shares of SMMT traded down $0.06 during trading hours on Wednesday, hitting $15.74. 811,298 shares of the company were exchanged, compared to its average volume of 4,608,931. The company has a market capitalization of $12.59 billion, a PE ratio of -13.96 and a beta of -1.49. The firm has a fifty day simple moving average of $16.15 and a 200-day simple moving average of $16.16. Summit Therapeutics has a one year low of $12.07 and a one year high of $29.23.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Summit Therapeutics in a report on Tuesday, September 22nd. Summit Redstone set a $25.00 price objective on shares of Summit Therapeutics in a research note on Wednesday, September 9th. Leerink Partners upgraded shares of Summit Therapeutics from an "underperform" rating to a "market perform" rating and raised their target price for the stock from $12.00 to $13.00 in a report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Finally, Guggenheim reissued a "buy" rating on shares of Summit Therapeutics in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $28.61.

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company's primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit's lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.